Clearmind Medicine Inc. (CMND) said that CMND-100, the company's proprietary psychedelic treatment has met the primary endpoint in a Phase I/IIa study in Alcohol Use Disorder (AUD). The stock is up more than 50% in pre-market trading.
The company said the study showed the drug candidate was well tolerated, with no serious adverse events reported in the third cohort and a favorable overall safety profile consistent with earlier cohorts.
Clearmind added that achieving the primary safety and tolerability endpoint, including at higher doses, supports further development of CMND-100 as a potential non-hallucinogenic treatment option for AUD.
Clearmind stock had closed at $0.7196 on Friday, down 13.77%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.